- Home
- LSTA vs BCTX Comparison
LSTA vs BCTX Comparison
Compare LSTA & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSTA
- BCTX
- Stock Information
- Founded
- LSTA 1980
- BCTX 2014
- Country
- LSTA United States
- BCTX Canada
- Employees
- LSTA N/A
- BCTX N/A
- Industry
- LSTA Misc Health and Biotechnology Services
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- LSTA Health Care
- BCTX Health Care
- Exchange
- LSTA Nasdaq
- BCTX Nasdaq
- Market Cap
- LSTA 20.9M
- BCTX 23.5M
- IPO Year
- LSTA N/A
- BCTX N/A
- Fundamental
- Price
- LSTA $2.94
- BCTX $3.11
- Analyst Decision
- LSTA Strong Buy
- BCTX Strong Buy
- Analyst Count
- LSTA 1
- BCTX 1
- Target Price
- LSTA $15.00
- BCTX $32.00
- AVG Volume (30 Days)
- LSTA 9.3K
- BCTX 359.2K
- Earning Date
- LSTA 08-11-2025
- BCTX 06-16-2025
- Dividend Yield
- LSTA N/A
- BCTX N/A
- EPS Growth
- LSTA N/A
- BCTX N/A
- EPS
- LSTA N/A
- BCTX N/A
- Revenue
- LSTA $1,000,000.00
- BCTX N/A
- Revenue This Year
- LSTA N/A
- BCTX N/A
- Revenue Next Year
- LSTA N/A
- BCTX N/A
- P/E Ratio
- LSTA N/A
- BCTX N/A
- Revenue Growth
- LSTA N/A
- BCTX N/A
- 52 Week Low
- LSTA $1.87
- BCTX $2.78
- 52 Week High
- LSTA $4.20
- BCTX $29.40
- Technical
- Relative Strength Index (RSI)
- LSTA 66.20
- BCTX 44.63
- Support Level
- LSTA $2.36
- BCTX $2.78
- Resistance Level
- LSTA $2.69
- BCTX $3.16
- Average True Range (ATR)
- LSTA 0.20
- BCTX 0.19
- MACD
- LSTA 0.01
- BCTX -0.01
- Stochastic Oscillator
- LSTA 90.77
- BCTX 40.24
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.